PI3K pathway inhibitors: Potential prospects as adjuncts to vaccine immunotherapy for glioblastoma

Taemin Oh, Michael E. Ivan, Matthew Z. Sun, Michael Safaee, Shayan Fakurnejad, Aaron J. Clark, Eli T. Sayegh, Orin Bloch, Andrew T. Parsa

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Constitutive activation of the PI3K pathway has been implicated in glioblastoma (GBM) pathogenesis. Pharmacologic inhibition can both inhibit tumor survival and downregulate expression of programmed death ligand-1, a protein highly expressed on glioma cells that strongly contributes to cancer immunosuppression. In that manner, PI3K pathway inhibitors can help optimize GBM vaccine immunotherapy. In this review, we describe and assess the potential integration of various classes of PI3K pathway inhibitors into GBM immunotherapy. While early-generation inhibitors have a wide range of immunosuppressive effects that could negate their antitumor potency, further work should better characterize how contemporary inhibitors affect the immune response. This will help determine if these inhibitors are truly a therapeutic avenue with a strong future in GBM immunotherapy.

Original languageEnglish (US)
Pages (from-to)737-753
Number of pages17
Issue number6
StatePublished - Jun 2014
Externally publishedYes


  • cancer
  • glioblastoma
  • immunotherapy
  • PI3K pathway inhibitor
  • treatment
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'PI3K pathway inhibitors: Potential prospects as adjuncts to vaccine immunotherapy for glioblastoma'. Together they form a unique fingerprint.

Cite this